Vertex Ebitda from 2010 to 2024

VRTX Stock  USD 465.73  2.40  0.51%   
Vertex Pharmaceuticals EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA is likely to outpace its year average in 2024. During the period from 2010 to 2024, Vertex Pharmaceuticals EBITDA regression line of annual values had significance of  0.000018 and arithmetic mean of  1,477,870,867. View All Fundamentals
 
EBITDA  
First Reported
1990-03-31
Previous Quarter
-3.3 B
Current Value
1.3 B
Quarterly Volatility
476.1 M
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vertex Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vertex Pharmaceuticals' main balance sheet or income statement drivers, such as Total Revenue of 10.4 B, Gross Profit of 9 B or Other Operating Expenses of 6.3 B, as well as many indicators such as Price To Sales Ratio of 10.09, Dividend Yield of 0.0 or PTB Ratio of 7.46. Vertex financial statements analysis is a perfect complement when working with Vertex Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Vertex Pharmaceuticals Correlation against competitors.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Latest Vertex Pharmaceuticals' Ebitda Growth Pattern

Below is the plot of the Ebitda of Vertex Pharmaceuticals over the last few years. It is Vertex Pharmaceuticals' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vertex Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Vertex Ebitda Regression Statistics

Arithmetic Mean1,477,870,867
Coefficient Of Variation133.34
Mean Deviation1,691,835,956
Median504,594,000
Standard Deviation1,970,582,596
Sample Variance3883195.8T
Range5.4B
R-Value0.88
Mean Square Error966650.9T
R-Squared0.77
Significance0.000018
Slope386,367,139
Total Sum of Squares54364740.7T

Vertex Ebitda History

20244.8 B
20234.6 B
20224.4 B
20212.9 B
20203.3 B
20191.5 B
2018663.2 M

About Vertex Pharmaceuticals Financial Statements

Vertex Pharmaceuticals investors use historical fundamental indicators, such as Vertex Pharmaceuticals' Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vertex Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA4.6 B4.8 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.